These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 25392091)
41. The role of targeted therapy in the treatment of colorectal cancer. Goldberg RM; Hurwitz HI; Fuchs CS Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241 [TBL] [Abstract][Full Text] [Related]
42. Cisplatin induces apoptosis of A549 cells by downregulating peroxidase V. Chen X; Wang KW; Chen YQ Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3718. PubMed ID: 31114996 [TBL] [Abstract][Full Text] [Related]
43. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE; Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727 [TBL] [Abstract][Full Text] [Related]
44. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H; Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430 [TBL] [Abstract][Full Text] [Related]
45. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068 [TBL] [Abstract][Full Text] [Related]
46. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. de Gramont A; Van Cutsem E Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835 [TBL] [Abstract][Full Text] [Related]
48. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Sánchez-Gundín J; Fernández-Carballido AM; Martínez-Valdivieso L; Barreda-Hernández D; Torres-Suárez AI Int J Med Sci; 2018; 15(7):659-665. PubMed ID: 29910669 [TBL] [Abstract][Full Text] [Related]
49. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598 [TBL] [Abstract][Full Text] [Related]
50. Lewy pathological study on α-synuclein in gastrointestinal tissues of prodromal Parkinson's disease. Lu QB; Zhu ZF; Zhang HP; Luo WF Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2007. PubMed ID: 28537689 [TBL] [Abstract][Full Text] [Related]
51. Preparation of icariin/TiO2 nanotube composite coating on pure titanium surface and analysis of early drug release. Wang FF; Li Y; Liu HC Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4064. PubMed ID: 31173273 [TBL] [Abstract][Full Text] [Related]
52. Targeting of miR-20a against CFLAR to potentiate TRAIL-induced apoptotic sensitivity in HepG2 cells. Wang Y; Zhao YR; Zhang AY; Ma J; Wang ZZ; Zhang X Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):2980. PubMed ID: 28742211 [TBL] [Abstract][Full Text] [Related]
55. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924 [TBL] [Abstract][Full Text] [Related]
56. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830 [TBL] [Abstract][Full Text] [Related]
57. Olanzapine inhibits the proliferation and induces the differentiation of glioma stem-like cells through modulating the Wnt signaling pathway in vitro. Guo QH; Yang HJ; Wang SD Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4455. PubMed ID: 26698236 [TBL] [Abstract][Full Text] [Related]